MIRA
INFORM REPORT
|
Report Date : |
18.01.2008 |
IDENTIFICATION
DETAILS
|
Name : |
ZINTA PHARMACEUTICAL INDUSTRIES |
|
|
|
|
Registered Office : |
168 - Industrial Estate Jamrud Road, Peshawar |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Date of Incorporation : |
2002 |
|
|
|
|
Legal Form : |
Proprietorship Business. |
|
|
|
|
Line of Business : |
Manufacture &
Marketing of Pharmaceutical Products. |
RATING &
COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
Status : |
Small Company |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
Business Name
ZINTA PHARMACEUTICAL INDUSTRIES
Full Address
Registered Address & Factory
168 - Industrial Estate Jamrud Road, Peshawar, Pakistan
Tel 92 (91) 5828762
Fax 92 (91) 5828601
Short Description Of Business
Nature of Business Manufacture & Marketing of Pharmaceutical
Products
Year
Established 2002
National
Tax # 0909806
Branches
None
Legal Status
Subject Company was established as a Proprietorship business in 2002
Details of Proprietor
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Muhammad Iqbal |
Pakistani |
168 - Industrial
Estate Jamrud Road, Peshawar |
Business |
Proprietor |
Associates
SUBSIDIARY
None
ASSOCIATED COMPANIES
None
Products
Subject Company is engaged in manufacture & marketing of Pharmaceutical Products.
It purchases raw material against D/A basis.
Its’ major customers are Distributors, Traders, Pharmacies & Hospitals located in Peshawar.
Subject operates from caption leased factory premises of area measuring 1,500 Sq.Yard. which is situated in industrial area.
Subject employs about 50 persons in its set up.
Products
ARVIN, AXOLEV, AXONOR,
BENCLAM, BIPROGESIC, BRONCODYL, CAFIMOL EXTRA, CLORIZAT, CORED, CRAMID,
CROBAMIN, DEJAFEN-S, DEJAFIN, DILOCAL, DINOMET, DOTEX, DROVID, EPIDINE,
EPIGARD, FADOPRIM, FORTARAN, FROGEN, KLORECAL, KLOZEN, LARTEX, LIRIN, LOMET,
LONOCIP, MINOMET, MORCIN, NEORADIX, NIDAMET, NIMEPAN, POLENOR, POLEX, POLVIN,
PONOFLOX, PONOLOX, RAPIDONE, RAZOMEP, RECLOCIN, ROBIAZOLE, SEDOFEN-FORTE,
SOVEX, TINADEME, TROBEL, VASCOZEM, VITIRON C, VITOSIN, ZEECAM, ZEEFOLIC,
ZILCIT, ZINTABION, ZINTACEF, ZINTAFEN, ZINTAGEL, ZINTAGEL FORT, ZINTAXIME,
ZINTAXON, ZITALAN, ZOLAX, ZOLICEF, ZOLOGEN, ZOLVIN, ZOVEX, ZOVIT,ZYLODROX
Annual Sales Volume
|
Year |
In Pak Rupees
|
|
2006 |
10,000,000/-
(Estimated) |
Capacity &
Production
The capacity and production of the company’s plant is indeterminable as it is multi- product and involves various processes of manufacture.
Authorized
Distributors
Mainly in Peshawar at present
Bankers
MCB Bank Limited, Pakistan.
Faysal Bank Limited, Pakistan.
Foreign Exchange
Rates
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 62.50 |
|
UK Pound |
1 |
Rs. 122.30 |
|
Euro |
1 |
Rs. 92.40 |
Comments
Subject Company was established in
2002 and is engaged in manufacture & marketing of Pharmaceutical Products. Trade relations are reported as fair. The Company
can be considered for normal business dealings at usual trade terms and
conditions.
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)